{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:06:00Z","timestamp":1790287560507,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Factor VIII (FVIII) circulates in a noncovalent complex with von Willebrand Factor (VWF), the latter determining FVIII half-life. The VWF-binding aptamer rondaptivon pegol (BT200) increases plasma levels of VWF\/FVIII in healthy volunteers. This trial assessed its safety, pharmacokinetics, and pharmacodynamics in hemophilia A. Nineteen adult patients (ages 20-62 years, 4 women) with hemophilia A (8 mild, 2 moderate, and 9\u00a0severe) received subcutaneous injections of rondaptivon pegol. After an initial fixed dose of 3 mg on days 0 and 4, patients received weekly doses of 2 to 9 mg until day 28. Severe hemophilia A patients underwent sparse-sampling population pharmacokinetics individual profiling after the final dose of rondaptivon pegol. Adverse events, pharmacokinetics, and pharmacodynamics were assessed. FVIII activity and VWF levels were measured. All patients tolerated rondaptivon pegol well. The geometric mean half-life of rondaptivon pegol was 5.4 days and rondaptivon pegol significantly increased VWF levels. In severe hemophilia A, 6 doses of rondaptivon pegol increased the half-lives of 5 different FVIII products from a median of 10.4 hours to 31.1 hours (range, 20.8-56.0 hours). Median FVIII increased from 22% to 48% in mild hemophilia A and from 3% to 7.5% in moderate hemophilia A. Rondaptivon pegol is a first-in-class prohemostatic molecule that extended the half-life of substituted FVIII approximately 3-fold and increased endogenous FVIII levels approximately 2-fold in hemophilia patients. This trial was registered at www.clinicaltrials.gov as #NCT04677803.<\/jats:p>","DOI":"10.1182\/blood.2022016571","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T17:18:25Z","timestamp":1663262305000},"page":"1147-1158","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["The von Willebrand factor\u2013binding aptamer rondaptivon pegol as a treatment for severe and\u00a0nonsevere hemophilia A"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"first","affiliation":[{"name":"1Clinical Division of Hematology and Hemastaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6774-714X","authenticated-orcid":false,"given":"Katarina D.","family":"Kovacevic","sequence":"additional","affiliation":[{"name":"2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-081X","authenticated-orcid":false,"given":"Daniel","family":"Kraemmer","sequence":"additional","affiliation":[{"name":"1Clinical Division of Hematology and Hemastaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-1077","authenticated-orcid":false,"given":"Christian","family":"Schoergenhofer","sequence":"additional","affiliation":[{"name":"2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-7178","authenticated-orcid":false,"given":"Georg","family":"Gelbenegger","sequence":"additional","affiliation":[{"name":"2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Firbas","sequence":"additional","affiliation":[{"name":"2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0122-8213","authenticated-orcid":false,"given":"Peter","family":"Quehenberger","sequence":"additional","affiliation":[{"name":"3Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Jilma-Stohlawetz","sequence":"additional","affiliation":[{"name":"3Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"4Guardian Therapeutics, Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhao","family":"Zhu","sequence":"additional","affiliation":[{"name":"4Guardian Therapeutics, Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Beliveau","sequence":"additional","affiliation":[{"name":"5Certara, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-3304","authenticated-orcid":false,"given":"Franz","family":"Koenig","sequence":"additional","affiliation":[{"name":"6CEMSIS, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-8766","authenticated-orcid":false,"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[{"name":"7Department of Health Research Methods, Evidence, and Impact and Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7977","authenticated-orcid":false,"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-8483","authenticated-orcid":false,"given":"Ulla","family":"Derhaschnig","sequence":"additional","affiliation":[{"name":"2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-9896","authenticated-orcid":false,"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"1Clinical Division of Hematology and Hemastaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2023103115014332300_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"issue":"23","key":"2023103115014332300_bib2","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023103115014332300_bib3","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood.2021011849","article-title":"Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis","volume":"138","author":"Zwagemaker","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023103115014332300_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.15189","article-title":"Mortality in congenital hemophilia A\u2014a systematic literature review","volume":"19","author":"Hay","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2023103115014332300_bib5","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1111\/hae.13166","article-title":"Comparative burden of arthropathy in mild haemophilia: a register-based study in Sweden","volume":"23","author":"Osooli","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"2023103115014332300_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1160\/TH10-07-0492","article-title":"High incidence of ankle arthropathy in mild and moderate haemophilia A","volume":"105","author":"Ling","year":"2011","journal-title":"Thromb Haemost"},{"issue":"suppl 6","key":"2023103115014332300_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, third edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"16","key":"2023103115014332300_bib8","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2023103115014332300_bib9","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1111\/bcp.14838","article-title":"Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective","volume":"87","author":"Tomeo","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"2023103115014332300_bib10","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023103115014332300_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2023103115014332300_bib12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1055\/s-0040-1714279","article-title":"Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A","volume":"120","author":"Gelbenegger","year":"2020","journal-title":"Thromb Haemost"},{"issue":"8","key":"2023103115014332300_bib13","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1111\/jth.15395","article-title":"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database","volume":"19","author":"Versloot","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2023103115014332300_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/hae.13777","article-title":"Burden of mild haemophilia A: systematic literature review","volume":"25","author":"Peyvandi","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"2023103115014332300_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hae.13616","article-title":"Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: the THUNDER study","volume":"25","author":"Scott","year":"2019","journal-title":"Haemophilia"},{"issue":"19","key":"2023103115014332300_bib16","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/bloodadvances.2020002626","article-title":"Inhibitors and mortality in persons with nonsevere hemophilia A in the United States","volume":"4","author":"Lim","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2023103115014332300_bib17","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1111\/jth.15419","article-title":"Treatment-related risk factors for inhibitor development in nonsevere hemophilia A after 50 cumulative exposure days: a case-control study","volume":"19","author":"Abdi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2023103115014332300_bib18","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3324\/haematol.2021.279948","article-title":"The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of VWF and factor VIII: a first-in-human trial","volume":"107","author":"Kovacevic","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"2023103115014332300_bib19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jth.14755","article-title":"The development and characterization of a long acting antithrombotic von Willebrand factor (VWF) aptamer","volume":"18","author":"Zhu","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2023103115014332300_bib20","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/jth.14785","article-title":"Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation","volume":"18","author":"Fazavana","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"S1","key":"2023103115014332300_bib21","first-page":"OC67.65","article-title":"VWFA1 interacts with scavenger receptor LRP1 via lysine 1408","volume":"3","author":"Chion","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"2023103115014332300_bib22","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jth.13867","article-title":"Estimating and interpreting the pharmacokinetics profiles of individual patients with hemophilia A or B using a population pharmacokinetics approach: communication from the SSC of the ISTH","volume":"15","author":"Iorio","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023103115014332300_bib23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/rth2.12106","article-title":"Performing and interpreting individual pharmacokinetics profiles in patients with hemophilia A or B: rationale and general considerations","volume":"2","author":"Iorio","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"2023103115014332300_bib24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"Ragni","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023103115014332300_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/hae.13977","article-title":"Development and evaluation of the population pharmacokinetics models for FVIII and FIX concentrates of the WAPPS-Hemo project","volume":"26","author":"Hajducek","year":"2020","journal-title":"Haemophilia"},{"issue":"4","key":"2023103115014332300_bib26","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.2196\/resprot.6558","article-title":"Development of a web-accessible population pharmacokinetics service\u2014hemophilia (WAPPS-Hemo): study protocol","volume":"5","author":"Iorio","year":"2016","journal-title":"JMIR Res Protoc"},{"issue":"6","key":"2023103115014332300_bib27","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1182\/blood-2010-08-299016","article-title":"Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman program for the molecular and clinical biology of VWD","volume":"117","author":"Flood","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2023103115014332300_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ajh.25393","article-title":"Automated assays for von Willebrand factor activity","volume":"94","author":"Higgins","year":"2019","journal-title":"Am J Hematol"},{"issue":"15","key":"2023103115014332300_bib29","doi-asserted-by":"crossref","first-page":"11044","DOI":"10.1074\/jbc.275.15.11044","article-title":"Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis","volume":"275","author":"Matsushita","year":"2000","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"2023103115014332300_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-82747-7","article-title":"The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients","volume":"11","author":"Kovacevic","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"2023103115014332300_bib31","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023103115014332300_bib32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023103115014332300_bib33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"issue":"11","key":"2023103115014332300_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023103115014332300_bib35","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1097\/HS9.0000000000000540","article-title":"Hemophilia gene therapy: approaching the first licensed product","volume":"5","author":"Batty","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"2023103115014332300_bib36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/hae.13831","article-title":"Joint comorbidities among Swedish carriers of haemophilia: a register-based cohort study over 22 years","volume":"25","author":"Osooli","year":"2019","journal-title":"Haemophilia"},{"issue":"8","key":"2023103115014332300_bib37","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/jth.15397","article-title":"A\u00a0new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH","volume":"19","author":"van Galen","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"16","key":"2023103115014332300_bib38","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2023103115014332300_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-2003-37944","article-title":"Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety","volume":"29","author":"Lethagen","year":"2003","journal-title":"Semin Thromb Hemost"},{"issue":"20","key":"2023103115014332300_bib40","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/bloodadvances.2018023713","article-title":"A\u00a0decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding","volume":"2","author":"Candy","year":"2018","journal-title":"Blood Adv"},{"key":"2023103115014332300_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2018.10.008","article-title":"Pharmacokinetics, pharmacodynamics and safety of aptamers","volume":"134","author":"Kovacevic","year":"2018","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/10\/1147\/2086538\/blood_bld-2022-016571-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/10\/1147\/2086538\/blood_bld-2022-016571-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:04:05Z","timestamp":1698750245000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/10\/1147\/486643\/The-von-Willebrand-factor-binding-aptamer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,3,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016571","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}